Hanyang Med Rev.  2012 Nov;32(4):179-186. 10.7599/hmr.2012.32.4.179.

Calcium Metabolism and Hyper and Hypoparathyroidism

Affiliations
  • 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. csshin@snu.ac.kr

Abstract

Calcium balance refers to the state of calcium body stores which are primarily in bone, determined largely as a function of dietary intake, intestinal absorption, renal excretion, and bone remodeling. Calcium homeostasis refers to the hormonal regulation of serum ionized calcium concentrations by parathyroid hormone (PTH), the release and effect of which is dependent on the availability of 1,25-dihydroxyvitamin D, and levels of serum ionized calcium, which together regulate calcium absorption and transport in the tissues of the gut, kidney, and bone. Primary hyperparathyroidism is diagnosed on the basis of a raised PTH level in the presence of hypercalcemia. Hypoparathyroidism refers to the failure of the body to produce levels of PTH sufficient to maintain a normal level of serum calcium. Pseudo-parathyroidismis characterized by end-organ resistance to PTH which presents as hypocalcemia and hyperphosphatemias under high PTH levels.

Keyword

Calcium; Hyperparathyroidism; Hypoparathyroidism

MeSH Terms

Absorption
Bone Remodeling
Calcium
Homeostasis
Hypercalcemia
Hyperparathyroidism
Hyperparathyroidism, Primary
Hyperphosphatemia
Hypocalcemia
Hypoparathyroidism
Intestinal Absorption
Kidney
Parathyroid Hormone
Vitamin D
Calcium
Parathyroid Hormone
Vitamin D

Figure

  • Fig. 1 Schematic presentation of the calcium metabolism. PTH, parathyroid hormone.


Reference

1. Peacock M. Calcium metabolism in health and disease. Clin J Am Soc Nephrol. 2010. 5 Suppl 1:S23–S30.
Article
2. O'Toole JF. Disorders of calcium metabolism. Nephron Physiol. 2011. 118:p22–p27.
3. Shoback D, Sellmeyer D, Bikle DD. Gardner DG, Shoback D, editors. Metabolic bone disease. Greenspan's basic & clinical endocrinology. 2011. 9th ed. New York: McGraw-Hill;227–241.
4. Bringhurst FR, Demay MB, Kronenberg HM. Melmed S PK, Larsen PR, Kronengerg HM, editors. Hormones and disorders of mineral metabolism. Williams textbook of endocrinology. 2011. 12th ed. Elsevier;1257–1260.
Article
5. Allgrove J. Physiology of calcium, phosphate and magnesium. Endocr Dev. 2009. 16:8–31.
Article
6. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009. 94:351–365.
Article
7. Marcocci C, Cetani F. Clinical practice. Primary hyperparathyroidism. N Engl J Med. 2011. 365:2389–2397.
8. Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006. 21:171–177.
Article
9. Cohen J, Gierlowski TC, Schneider AB. A prospective study of hyperparathyroidism in individuals exposed to radiation in childhood. JAMA. 1990. 264:581–584.
Article
10. Szalat A, Mazeh H, Freund HR. Lithium-associated hyperparathyroidism: report of four cases and review of the literature. Eur J Endocrinol. 2009. 160:317–323.
Article
11. Marx SJ. Hyperparathyroid genes: sequences reveal answers and questions. Endocr Pract. 2011. 17:Suppl 3. 18–27.
Article
12. Rejnmark L, Vestergaard P, Mosekilde L. Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab. 2011. 96:2377–2385.
Article
13. Ayturk S, Gursoy A, Bascil Tutuncu N, Ertugrul DT, Guvener Demirag N. Changes in insulin sensitivity and glucose and bone metabolism over time in patients with asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. 2006. 91:4260–4263.
Article
14. Hagstrom E, Lundgren E, Lithell H, Berglund L, Ljunghall S, Hellman P, et al. Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years. Clin Endocrinol (Oxf). 2002. 56:253–260.
Article
15. Walker MD, Silverberg SJ. Cardiovascular aspects of primary hyperparathyroidism. J Endocrinol Invest. 2008. 31:925–931.
Article
16. Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 2000. 321:598–602.
Article
17. Bilezikian JP, Khan AA, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009. 94:335–339.
Article
18. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008. 93:3462–3470.
Article
19. Bollerslev J, Jansson S, Mollerup CL, Nordenstrom J, Lundgren E, Torring O, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab. 2007. 92:1687–1692.
Article
20. Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti C, Viccica G, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab. 2007. 92:3114–3121.
Article
21. Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. 2004. 89:5415–5422.
Article
22. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007. 92:3001–3005.
Article
23. Soreide JA, van Heerden JA, Grant CS, Yau Lo C, Schleck C, Ilstrup DM. Survival after surgical treatment for primary hyperparathyroidism. Surgery. 1997. 122:1117–1123.
Article
24. Yu N, Donnan PT, Flynn RW, Murphy MJ, Smith D, Rudman A, et al. Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf). 2010. 73:30–34.
25. Jacobs TP, Bilezikian JP. Clinical review: Rare causes of hypercalcemia. J Clin Endocrinol Metab. 2005. 90:6316–6322.
26. Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009. 94:340–350.
Article
27. Silverberg SJ. Vitamin D deficiency and primary hyperparathyroidism. J Bone Miner Res. 2007. 22:suppl 2. V100–V104.
Article
28. Suh JM, Cronan JJ, Monchik JM. Primary hyperparathyroidism: is there an increased prevalence of renal stone disease. AJR Am J Roentgenol. 2008. 191:908–911.
Article
29. Silverberg SJ, Locker FG, Bilezikian JP. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab. 1996. 81:4007–4012.
Article
30. Udelsman R, Lin Z, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg. 2011. 253:585–591.
Article
31. Vignali E, Picone A, Materazzi G, Steffe S, Berti P, Cianferotti L, et al. A quick intraoperative parathyroid hormone assay in the surgical management of patients with primary hyperparathyroidism: a study of 206 consecutive cases. Eur J Endocrinol. 2002. 146:783–788.
Article
32. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med. 1996. 125:360–368.
Article
33. Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004. 89:3319–3325.
Article
34. Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab. 2009. 94:2766–2772.
Article
35. Bilezikian JP, Khan A, Potts JT Jr, Brandi ML, Clarke BL, Shoback D, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011. 26:2317–2337.
Article
36. Chan FK, Tiu SC, Choi KL, Choi CH, Kong AP, Shek CC. Increased bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab. 2003. 88:3155–3159.
Article
37. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med. 2000. 343:1863–1875.
Article
38. Percival RC, Hargreaves AW, Kanis JA. The mechanism of hypocalcaemia following thyroidectomy. Acta Endocrinol (Copenh). 1985. 109:220–226.
Article
39. Richards ML, Thompson GB, Farley DR, Grant CS. Reoperative parathyroidectomy in 228 patients during the era of minimal-access surgery and intraoperative parathyroid hormone monitoring. Am J Surg. 2008. 196:937–942.
Article
40. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med. 2004. 350:2068–2079.
Article
41. Blizzard RM, Chee D, Davis W. The incidence of parathyroid and other antibodies in the sera of patients with idiopathic hypoparathyroidism. Clin Exp Immunol. 1966. 1:119–128.
42. Li Y, Song YH, Rais N, Connor E, Schatz D, Muir A, et al. Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism. J Clin Invest. 1996. 97:910–914.
Article
43. Thakker RV. Genetic developments in hypoparathyroidism. Lancet. 2001. 357:974–976.
Article
44. Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with Thalassaemia Major. Pediatr Endocrinol Rev. 2007. 5:642–648.
45. Carpenter TO, Carnes DL Jr, Anast CS. Hypoparathyroidism in Wilson's disease. N Engl J Med. 1983. 309:873–877.
Article
46. Tong GM, Rude RK. Magnesium deficiency in critical illness. J Intensive Care Med. 2005. 20:3–17.
Article
47. Chase LR, Melson GL, Aurbach GD. Pseudohypoparathyroidism: defective excretion of 3',5'-AMP in response to parathyroid hormone. J Clin Invest. 1969. 48:1832–1844.
Article
48. Weinstein LS, Yu S, Warner DR, Liu J. Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev. 2001. 22:675–705.
Article
49. Bastepe M. The GNAS locus and pseudohypoparathyroidism. Adv Exp Med Biol. 2008. 626:27–40.
Article
50. Mantovani G, de Sanctis L, Barbieri AM, Elli FM, Bollati V, Vaira V, et al. Pseudohypoparathyroidism and GNAS epigenetic defects: clinical evaluation of albright hereditary osteodystrophy and molecular analysis in 40 patients. J Clin Endocrinol Metab. 2010. 95:651–658.
Article
Full Text Links
  • HMR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr